Loading company
Citius Oncology, Inc.
CTOR · Nasdaq · ·
$1.060.0%Sep 29 close
- 1M
- +36.7%
- 6M
- +115.0%
- 1Y
- -47.8%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$1.49MQ2 2026-10.4%
Everything the company sold, before any costs. Each quarter on its own, so seasonal highs and lows are visible.
-$46.06MQ2 2026-8.4%
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-$0.47Q2 20260.0%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
93.45MQ2 2026+10.8%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
122.8xQ1 2024+214.2%
122.8x today · median 55.4x and range 39.1x–122.8x across the points shown, Q2 2023 to Q1 2024
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
Everything above comes from Citius Oncology, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 50.31x around Sep 30, 2023, 0.10x around Dec 31, 2023, and 10.31x around Sep 30, 2024. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Capital Expenditures, Dividends paid, Depreciation & Amortization, Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
CTOR · Nasdaq · ·
$1.060.0%Sep 29 close